Novelion Therapeutics Inc, a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-500-7867
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$130.43 million
Profitability
Miscellaneous
Employees109
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Novelion Therapeutics (NASDAQ:NVLN) Frequently Asked Questions
What is Novelion Therapeutics' stock symbol?
Novelion Therapeutics trades on the NASDAQ under the ticker symbol "NVLN."
How were Novelion Therapeutics' earnings last quarter?
Novelion Therapeutics Inc (NASDAQ:NVLN) posted its earnings results on Thursday, March, 14th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by $0.13. The biotechnology company earned $40.71 million during the quarter, compared to analysts' expectations of $40.90 million. View Novelion Therapeutics' Earnings History.
When is Novelion Therapeutics' next earnings date?
What is the consensus analysts' recommendation for Novelion Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novelion Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novelion Therapeutics.
Has Novelion Therapeutics been receiving favorable news coverage?
News coverage about NVLN stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Novelion Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Novelion Therapeutics.
Are investors shorting Novelion Therapeutics?
Novelion Therapeutics saw a decline in short interest in the month of September. As of September 15th, there was short interest totalling 63,000 shares, a decline of 32.9% from the August 15th total of 93,900 shares. Based on an average trading volume of 97,800 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.4% of the company's shares are sold short. View Novelion Therapeutics' Current Options Chain.
Who are some of Novelion Therapeutics' key competitors?
Some companies that are related to Novelion Therapeutics include Ophthotech (OPHT), VERONA PHARMA P/S (VRNA), Catabasis Pharmaceuticals (CATB), Iterum Therapeutics (ITRM), Pharmaxis (PXSLY), Merrimack Pharmaceuticals (MACK), Aridis Pharmaceuticals (ARDS), OTCMKTS:EMBI (EMBI), Agile Therapeutics (AGRX), Oramed Pharmaceuticals (ORMP), Arbutus Biopharma (ABUS), ESSA Pharma (EPIX), Eyenovia (EYEN), SUMMIT THERAPEU/S (SMMT) and NewLink Genetics (NLNK).
What other stocks do shareholders of Novelion Therapeutics own?
Who are Novelion Therapeutics' key executives?
Novelion Therapeutics' management team includes the folowing people:
- Mr. Benjamin S. Harshbarger, Interim CEO, Gen. Counsel & Corp. Sec. (Age 50)
- Mr. Michael D. Price, Exec. VP & CFO (Age 61)
- Mr. Roger W. Louis, Global Chief Compliance Officer and Head of R&D (Age 63)
- Ms. Barbara Y. Chan, VP & Chief Accounting Officer (Age 55)
- Ms. Amanda Murphy, Director of Investor Relations & Corp. Communications
How do I buy shares of Novelion Therapeutics?
Shares of NVLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Novelion Therapeutics' stock price today?
One share of NVLN stock can currently be purchased for approximately $0.68.
How big of a company is Novelion Therapeutics?
What is Novelion Therapeutics' official website?
How can I contact Novelion Therapeutics?
Novelion Therapeutics' mailing address is 1800 - 510 WEST GEORGIA STREET, VANCOUVER A1, V6B 0M3. The biotechnology company can be reached via phone at 617-500-7867 or via email at [email protected]
MarketBeat Community Rating for Novelion Therapeutics (NASDAQ NVLN)
MarketBeat's community ratings are surveys of what our community members think about Novelion Therapeutics and other stocks. Vote "Outperform" if you believe NVLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
